Isotopically-stabilized tetronimide compounds
US10961211B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Feb 14, 2020 |
| Grant date | Mar 30, 2021 |
| Priority date | — |
| Expiry date | Feb 14, 2040 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07B2200/05
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
Isotopically-stabilized tetronimide compounds comprising one or more deuterium atoms, derivatives, and intermediates, thereof, including methods for their synthesis, pharmaceutical compositions thereof, and methods of using these compounds to interact with target molecules in cell-free samples, cell- and tissue-based assays, animal models, and in a subject are disclosed. One aspect relates to molecules that modulate the expression or catalytic activity of aspartyl (asparaginyl) β-hydroxylase (ASPH) within or on the surface of a cell. Other aspects of the invention relate to use of the molecules disclosed herein to diagnose, ameliorate, or treat cell proliferation disorders and related diseases. Related aspects include uses of the compounds to modulate the activity of viruses, as anti-hyperlipidemia agents, and as agents to ameliorate or treat thrombosis and related cardiovascular and metabolic disorders.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.